Ledisept pessary 16 mg. №10

$23.00

Manufacturer: Ukraine

Prevention of venereal diseases (syphilis, gonorrhea, trichomoniasis, chlamydia, ureaplasmosis) and infectious and inflammatory complications in obstetrics and gynecology (before surgical treatment of gynecological diseases, before childbirth and abortion, before and after the installation of an intrauterine spiral, before and after diathermocoagulation of the cervix, before intrauterine examinations).

Category:

Description

Ledisept Storage

active substance: chlorhexidine;

1 pessary contains chlorhexidine bigluconate, 20% solution corresponding to chlorhexidine 16 mg;

excipient: polyethylene oxide.

Ledisept Dosage form

Pessaries.

Main physical and chemical properties: pessaries from white to white with a yellowish tinge, marbling of the surface is allowed. The presence of a funnel-shaped recess and an air rod is allowed.

Ledisept Pharmacotherapeutic group.

Antimicrobial and antiseptic agents used in gynecology. ATX code G01A X.

Ledisept Pharmacological properties.

Pharmacodynamics.

Chlorhexidine bigluconate has a rapid and pronounced effect on gram-positive and gram-negative bacteria, yeast and dermatophytes: Treponema pallidum, Chlamidia spp., Ureaplasma spp., Neisseria gonorrhoeae, Trichomonas vaginalis. Some strains of Pseudomonas spp., Proteus spp. Are weakly sensitive to the drug. Insensitive to the drug acid-resistant forms of bacteria, bacterial spores, fungi, viruses.

Pharmacokinetics.

When administered intravaginally, it is practically not absorbed, has no systemic effect.

Clinical characteristics.

Indication.

Prevention of sexually transmitted diseases (syphilis, gonorrhea, trichomoniasis, chlamydia, ureaplasmosis) and infectious and inflammatory complications in obstetrics and gynecology (before surgical treatment of gynecological diseases, before childbirth and abortion, before and after IUD insertion, before and after the uterine spiral, before and after intrauterine studies).

Treatment of bacterial vaginosis, colpitis, cervical erosion.

Contraindication.

Individual hypersensitivity to the components of the drug.

Interaction with other medicinal products and other forms of interaction.

Chlorhexidine bigluconate should not be used with detergents that contain an anionic group (saponins, sodium lauryl sulfate, sodium carboxymethylcellulose), as well as with soap.

Features of application.

Use during pregnancy or breastfeeding.

Not contraindicated.

Ability to influence the speed of reaction when driving a car or other machinery.

Does not affect.

Method of application and dosage.

The drug is used intravaginally. Before use, release the pessary from the contour packaging.

Treatment: apply 1 pessary 2 times a day for 7-10 days, depending on the nature of the disease. If necessary, it is possible to extend the course of treatment for up to 20 days.

Prevention of sexually transmitted diseases: apply 1 pessary once no later than 2 hours after sexual intercourse.

Pregnancy. Due to the severity of the infectious process, bacteriological studies, the threat of abortion chlorhexidine bigluconate to use 1 pessary 1 or 2 times a day as monotherapy or as part of combination therapy. Duration of use – from 5 to 10 days.

When breastfeeding, the drug should be used in the usual recommended doses.

Children.

No experience.